BridgeBio director sells 10,000 shares after option exercise

BridgeBio Pharma director Scott Randal W. exercised stock options for 10,000 shares of common stock at $16.75 per share and sold 10,000 shares in open-market transactions on May 15, 2026.

Rhea-AI Filing Summary

BridgeBio Pharma director Scott Randal W. exercised stock options for 10,000 shares of common stock at $16.75 per share and sold 10,000 shares in open-market transactions on May 15, 2026. The sales occurred in multiple trades at weighted average prices around the high‑$60 range under a pre-arranged Rule 10b5-1 sales plan. Following these transactions, he holds 11,589 shares directly and 4,000 shares indirectly through Thinking Bench Capital LLC.

Insider Trade Summary 10b5-1

Exercise and Sale: 10,000 shares ($504K approx. pre-tax spread)

Exercise and Sale 7 txns

Insider Scott Randal W.

Role Director

Sold 10,000 shs ($671K)

Approx. gross sale proceeds $671K

Approx. exercise cost $168K

Approx. pre-tax spread $504K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	10,000	$0.00	$0.00
Exercise	Common Stock	10,000	$16.75	$168K
Sale	Common Stock	6,200	$66.6878	$413K
Sale	Common Stock	2,088	$67.5302	$141K
Sale	Common Stock	1,512	$68.2303	$103K
Sale	Common Stock	200	$69.12	$14K
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 21,501 contracts (Direct); Common Stock — 11,589 shares (Direct); Common Stock — 4,000 shares (Indirect, By Thinking Bench Capital LLC)

Footnotes (5)

1. F1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 27, 2025.
2. F2. Represents the weighted average sale price of the shares sold from $66.08 to $67.07 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
3. F3. Represents the weighted average sale price of the shares sold from $67.10 to $68.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
4. F4. Represents the weighted average sale price of the shares sold from $68.10 to $68.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
5. F5. One-third of the shares underlying the option will vest on June 21, 2024; thereafter, one-third of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company.

Key Figures

Shares sold: 10,000 shares Sale prices: $66.69–$69.12 per share Options exercised: 10,000 shares +4 more

7 metrics

Shares sold 10,000 shares Open-market sales of common stock on May 15, 2026

Sale prices $66.69–$69.12 per share Weighted average prices across four sale blocks

Options exercised 10,000 shares Stock option exercise (Code M) on May 15, 2026

Exercise price $16.75 per share Stock Option (Right to Buy) conversion price

Direct holdings after 11,589 shares Common stock directly owned after transactions

Indirect holdings after 4,000 shares Common stock held via Thinking Bench Capital LLC

Net share change 10,000 shares ExerciseShares 10,000 vs. SellShares 10,000 (net-sell direction)

Key Terms

Rule 10b5-1 sales plan, weighted average sale price, Stock Option (Right to Buy), Board of Directors, +1 more

5 terms

Rule 10b5-1 sales plan regulatory

"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person"

weighted average sale price financial

"Represents the weighted average sale price of the shares sold from $66.08 to $67.07 per share"

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) with an exercise or conversion price of 16.7500"

Board of Directors financial

"subject to the optionee's continued service on the Board of Directors of the Company"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

derivative exercise/conversion financial

"transaction_action: derivative exercise/conversion with transaction code M"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did BridgeBio Pharma (BBIO) report for Scott Randal W.?

BridgeBio Pharma reported that director Scott Randal W. exercised stock options for 10,000 shares and sold 10,000 common shares in open-market transactions. These trades occurred on May 15, 2026, and were executed under a pre-arranged Rule 10b5-1 sales plan.

How many BridgeBio Pharma (BBIO) shares did the director sell and at what prices?

The director sold 10,000 BridgeBio Pharma common shares in several trades at weighted average prices in the mid-to-high $60 range. Individual transactions included prices such as $69.12, $68.23, $67.53, and $66.69 per share across separate sale blocks.

What stock options did the BridgeBio Pharma (BBIO) director exercise?

The director exercised stock options covering 10,000 BridgeBio Pharma common shares at an exercise price of $16.75 per share. These options were part of a grant that vests in three annual installments, fully vesting by June 21, 2026, contingent on continued board service.

Were the BridgeBio Pharma (BBIO) insider sales made under a trading plan?

Yes. The filing states the sales were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. Such plans pre-schedule trades, meaning the timing of these sales was determined in advance rather than being a discretionary, real-time market decision.

How many BridgeBio Pharma (BBIO) shares does the director own after these transactions?

After the reported transactions, the director holds 11,589 BridgeBio Pharma common shares directly and 4,000 shares indirectly. The indirect position is held through Thinking Bench Capital LLC, reflecting additional economic exposure to the company beyond his direct holdings.

What is the nature of the indirect BridgeBio Pharma (BBIO) holdings in this Form 4?

The Form 4 shows 4,000 BridgeBio Pharma common shares held indirectly through Thinking Bench Capital LLC. This indicates the reporting person’s economic interest is partly held via that entity, rather than solely in his own name as directly owned stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/19/2026 - 04:25 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Scott Randal W.

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/15/2026		M(1)		10,000	A	$16.75	21,589	D
Common Stock	05/15/2026		S(1)		6,200	D	$66.6878(2)	15,389	D
Common Stock	05/15/2026		S(1)		2,088	D	$67.5302(3)	13,301	D
Common Stock	05/15/2026		S(1)		1,512	D	$68.2303(4)	11,789	D
Common Stock	05/15/2026		S(1)		200	D	$69.12	11,589	D
Common Stock								4,000	I	By Thinking Bench Capital LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$16.75	05/15/2026		M(1)			10,000	(5)	06/21/2033	Common Stock	10,000	$0	21,501	D

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 27, 2025.

2. Represents the weighted average sale price of the shares sold from $66.08 to $67.07 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

3. Represents the weighted average sale price of the shares sold from $67.10 to $68.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

4. Represents the weighted average sale price of the shares sold from $68.10 to $68.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

5. One-third of the shares underlying the option will vest on June 21, 2024; thereafter, one-third of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company.

Remarks:

	/s/ Laura Woodhead, Attorney-in-Fact	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)